
On Tuesday, British medtech company Smith & Nephew, a competitor of Coloplast within wound care, has announced a CEO replacement in connection with the release of its full-year financial figures. The double news has been rewarded well on the London stock exchange, sending the company up by 2.1 percent to GBP 12.04.
Deepak Nath has been appointed to replace Roland Diggelmann, who leaves Smith & Nephew after two years serving as CEO – a period during which the company’s stock value dropped by one fourth.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app